Journal
NATURE REVIEWS IMMUNOLOGY
Volume 15, Issue 1, Pages 45-56Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nri3790
Keywords
-
Categories
Ask authors/readers for more resources
Dysfunctional T cells can render the immune system unable to eliminate infections and cancer. Therapeutic targeting of the surface receptors that inhibit T cell function has begun to show remarkable success in clinical trials. In this Review, we discuss the potential mechanisms of action of the clinical agents that target two of these receptors, programmed cell death protein 1 (PD1) and lymphocyte activation gene 3 protein (LAG3). We also suggest correlative studies that may define the predominant mechanisms of action and identify predictive biomarkers.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available